Developing targeted therapies for a rare soft tissue cancer
Targeting EWS-ATF1 Fusion in Clear Cell Sarcoma of Soft Tissue
This study is looking for new ways to treat clear cell sarcoma, a rare and tough cancer that mostly affects teens and young adults, by focusing on a specific gene that helps the cancer grow, with the hope of offering better options for those who haven't had success with current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10994076 on NIH RePORTER |
What this research studies
This research focuses on creating new targeted treatments for clear cell sarcoma of soft tissue (CCSST), a rare and aggressive cancer that primarily affects adolescents and young adults. The study aims to understand how these therapies work, particularly targeting the EWS-ATF1 fusion gene that drives the cancer's growth. Current treatments are limited and often ineffective, making this research crucial for improving patient outcomes. By exploring novel approaches, the research seeks to provide better options for patients who have limited responses to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are adolescents and young adults diagnosed with clear cell sarcoma of soft tissue.
Not a fit: Patients with other types of cancers or those who do not have clear cell sarcoma of soft tissue may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments for a cancer that currently has no cure, significantly improving survival rates for affected patients.
How similar studies have performed: While targeted therapies for other cancers have shown promise, this specific approach for CCSST is novel and has not been extensively tested.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Li, Bingbing — Oregon Health & Science University
- Study coordinator: Li, Bingbing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.